Cargando…
Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)
BACKGROUND: Asbestos is the main cause of MPM in industrialized countries. Even since asbestos is banned in most developed countries, the peak wave of MPM incidence is anticipated for the next years due to the long latency of asbestos induced MPM. MPM patients not eligible for surgical procedures li...
Autores principales: | Petrausch, Ulf, Schuberth, Petra C, Hagedorn, Christian, Soltermann, Alex, Tomaszek, Sandra, Stahel, Rolf, Weder, Walter, Renner, Christoph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585825/ https://www.ncbi.nlm.nih.gov/pubmed/23259649 http://dx.doi.org/10.1186/1471-2407-12-615 |
Ejemplares similares
-
Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells
por: Schuberth, Petra C, et al.
Publicado: (2013) -
FAP-specific re-directed T cells first in-man study in malignant pleural mesothelioma: experience of the first patient treated
por: Pircher, Magdalena, et al.
Publicado: (2015) -
Pre-clinical testing of malignant fibroblast activation protein-specific re-directed T cells for treatment of pleural mesothelioma
por: Schuberth, Petra C, et al.
Publicado: (2013) -
Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis
por: Thies, Svenja, et al.
Publicado: (2015) -
CD74: a new prognostic factor for patients with malignant pleural mesothelioma
por: Otterstrom, C, et al.
Publicado: (2014)